PDA’s first aging facilities survey suggests that post-approval changes play a major part in slowing pharmaceutical industry investment in new technology. Fewer pharmaceutical companies even do “technology scouting” today.

	Maik Jornitz, who chaired the aging facilities taskforce during its first year, discusses challenges and what is required for change.

Facility Design and Engineering

Manufacturing

Quality Systems

Supply Chain

Pharmaceutical Technology-11-15-2016

PDA’s first aging facilities survey suggests that post-approval changes play a major part in slowing pharmaceutical industry investment in new technology.